Fosun Pharma, Kite Pharma To Set Up Cancer Treatment Joint Venture In China

Jillian Yue
January 11, 2017 — 11:43 CST

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Related Topics: biotech California Cancer drug China china healthcare Fosun Pharma healthcare Joint venture kite pharma manufacturing pharmaceutical Renminbi Shanghai

Related News:

Chinese AI Unicorn Zhipu AI Secures Major Funding Amid Competitive Landscape

September 19, 2024 — 01:18

Zhipu AI Unveils New Products and Announces Further Price Cuts as GenAI Price Wars Deepen in China

June 7, 2024 — 00:11

ByteDance Eyes AI Hardware, Exploring Wearable Earphones and Handheld AI Devices, Inspired by Microsoft’s Ecosystem Strategy

May 30, 2024 — 07:34

ByteDance’s Generative AI Play: Innovations vs. Pricing Wars – Will the App-Centric Strategy Prevail in the AI Era?

May 21, 2024 — 02:52

Decoding China’s Top Ten Generative AI Models: Established Tech Old Guards Lead the Charge in the GenAI Era

May 16, 2024 — 01:59

Hong Kong’s Bitcoin and Ethereum Spot ETFs Suffer Disappointing Debut, Yet Hope for Future Growth Persists

April 30, 2024 — 23:36

ByteDance’s Pragmatic AI Strategy: A Factor in Its Lag Behind OpenAI and Its Approach to Catching Up

April 24, 2024 — 00:28

SenseTime Grapples with Losses a Decade After Its Inception, Pinning Hopes on Generative AI to Drive Profitability

April 3, 2024 — 00:56

Demand Surges for $30 AI-Generated Videos of Deceased Loved Ones in China, Sparking Ethical and Intellectual Property Concerns

March 20, 2024 — 02:08

Franchising and Licensing Asia (FLAsia) 2024